{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:03:57Z","timestamp":1793851437388,"version":"4.6.1"},"reference-count":159,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1053\/j.gastro.2025.09.038","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T15:58:29Z","timestamp":1763654309000},"page":"1397-1448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn\u2019s Disease"],"prefix":"10.1053","volume":"169","author":[{"given":"Frank I.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin N.","family":"Ananthakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Click","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Syal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Haydek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Kappelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2025.09.038_bib1","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.15585\/mmwr.mm6542a3","article-title":"Prevalence of inflammatory bowel disease among adults aged \u226518 years \u2014 United States, 2015","volume":"65","author":"Dahlhamer","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1053\/j.gastro.2025.09.038_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib3","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib4","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/gutjnl-2013-305607","article-title":"Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979\u20132011","volume":"63","author":"Rungoe","year":"2014","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.09.038_bib5","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1007\/s10620-021-07200-1","article-title":"Systematic review and meta-analysis: risk of hospitalization in patients with ulcerative colitis and Crohn's Disease in population-based cohort studies","volume":"67","author":"Tsai","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2025.09.038_bib6","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1053\/j.gastro.2021.04.023","article-title":"AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease","volume":"160","author":"Singh","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/gutjnl-2016-312648","article-title":"Development of an index to define overall disease severity in IBD","volume":"67","author":"Siegel","year":"2018","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.09.038_bib8","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/j.gastro.2014.07.022","article-title":"Crohn\u2019s disease evaluation and treatment: clinical decision tool","volume":"147","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cgh.2013.02.001","article-title":"The AGA institute process for developing clinical practice guidelines part one: grading the evidence","volume":"11","author":"Sultan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib10","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1053\/j.gastro.2025.08.032","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe Crohn\u2019s disease: 2025 AGA evidence synthesis","volume":"169","author":"Singh","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib11","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.7326\/M22-0514","article-title":"A framework for the development of living practice guidelines in health care","volume":"175","author":"El Mikati","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2025.09.038_bib12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1053\/j.gastro.2023.09.029","article-title":"AGA clinical practice guideline on the role of biomarkers for the management of Crohn's disease","volume":"165","author":"Ananthakrishnan","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.dld.2016.09.009","article-title":"Patient preferences for inflammatory bowel disease treatment objectives","volume":"49","author":"Casellas","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1053\/j.gastro.2025.09.038_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib15","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1053\/j.gastro.2025.09.038_bib17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2024.10.009","article-title":"Placebo rates in Crohn's disease randomized clinical trials: an individual patient data meta-analysis","volume":"168","author":"Solitano","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2025.09.038_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2025.09.038_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074495","article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","volume":"381","author":"Izcovich","year":"2023","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2025.09.038_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"10.1053\/j.gastro.2025.09.038_bib22","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1093\/ibd\/izaf085","article-title":"Developing IBD outcome effect size thresholds to inform research, guidelines, and clinical decisions","volume":"31","author":"Gordon","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2025.09.038_bib23","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2025.09.038_bib24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S2468-1253(20)30300-9","article-title":"Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis","volume":"5","author":"Fairbrass","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11938-021-00364-9","article-title":"Health maintenance for adult patients with inflammatory bowel disease","volume":"19","author":"Hashash","year":"2021","journal-title":"Cur Treat Options Gastroenterol"},{"key":"10.1053\/j.gastro.2025.09.038_bib26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","volume":"8","author":"Long","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib28","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2025.09.038_bib29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.09.038_bib30","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.09.038_bib31","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib32","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.09.038_bib33","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial","volume":"130","author":"Lemann","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib34","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.09.038_bib35","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY)","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib36","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib38","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.09.038_bib39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","article-title":"Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease","volume":"6","author":"Watanabe","year":"2012","journal-title":"J Crohns Colitis"},{"key":"10.1053\/j.gastro.2025.09.038_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820938960","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial","volume":"13","author":"Chen","year":"2020","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1053\/j.gastro.2025.09.038_bib41","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2025.09.038_bib42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib43","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND Trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib44","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.09.038_bib45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.09.038_bib46","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cgh.2010.04.021","article-title":"Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab","volume":"8","author":"Sandborn","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib47","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.09.038_bib48","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00535-019-01647-w","article-title":"Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses","volume":"55","author":"Watanabe","year":"2020","journal-title":"J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.09.038_bib50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn's disease: results from the VISIBLE 2 randomised trial","volume":"16","author":"Vermeire","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1053\/j.gastro.2025.09.038_bib51","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.09.038_bib52","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.09.038_bib53","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib54","doi-asserted-by":"crossref","first-page":"1057b2","DOI":"10.1016\/S0016-5085(24)05019-4","article-title":"Efficacy and safety of guselkumab therapy in patients with moderately to severely active Crohn's disease: results of the GALAXI 2 & 3 phase 3 studies","volume":"166","author":"Panaccione","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib55","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn's disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib56","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.09.038_bib57","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn's disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib58","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/j.gastro.2025.02.033","article-title":"Efficacy and safety of guselkumab subcutaneous induction and maintenance in participants with moderately to severely active Crohn\u2019s disease: results from the phase 3 GRAVITI study","volume":"169","author":"Hart","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib59","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens","year":"2022","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.09.038_bib60","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.09.038_bib61","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.09.038_bib62","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.09.038_bib63","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib64","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/ecco-jcc\/jjad100","article-title":"Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and meta-analysis","volume":"17","author":"Solitano","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1053\/j.gastro.2025.09.038_bib66","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/ajg.2016.433","article-title":"Crohn's disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab","volume":"111","author":"Osterman","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.09.038_bib67","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.09.038_bib68","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.cgh.2024.01.003","article-title":"Impact of treatment response on risk of serious infections in patients with Crohn's disease: secondary analysis of the PYRAMID registry","volume":"22","author":"Ahuja","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib69","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/ibd\/izy321","article-title":"Improved quality of life with anti-TNF therapy compared with continued corticosteroid utilization in Crohn's disease","volume":"25","author":"Scott","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2025.09.038_bib70","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.cgh.2019.05.010","article-title":"Variation among patients with Crohn's disease in benefit vs risk preferences and remission time equivalents","volume":"18","author":"Bewtra","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib71","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000629","article-title":"A comparison of treatment effect sizes in matched phase 2 and phase 3 trials of advanced therapeutics in inflammatory bowel disease: systematic review and meta-analysis","volume":"14","author":"Hanzel","year":"2023","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1053\/j.gastro.2025.09.038_bib72","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"Jorgensen","year":"2017","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2025.09.038_bib73","article-title":"P0990 Real-world effectiveness of upadacitinib induction therapy in Crohn\u2019s disease, with a focus on patients with concomitant IMIDs","volume":"19","author":"Elosua Gonzalez","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"Suppl","key":"10.1053\/j.gastro.2025.09.038_bib74","doi-asserted-by":"crossref","first-page":"S936","DOI":"10.14309\/01.ajg.0001034600.37922.a6","article-title":"S1308 Treatment outcomes of prolonged induction or re-escalation dosing of upadacitinib in patients with inflammatory bowel disease","volume":"119","author":"Axenfeld","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.09.038_bib75","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.cgh.2024.12.023","article-title":"Extended risankizumab treatment in patients with Crohn's disease who did not achieve clinical response to induction treatment","volume":"23","author":"Panaccione","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl","key":"10.1053\/j.gastro.2025.09.038_bib76","first-page":"S576","article-title":"Abstract MP582. Guselkumab maintenance dose regimens in patients with high disease activity and severity: subgroup analysis of participants with moderately to severely active Crohn's disease in the GALAXI phase 3 studies","volume":"13","author":"Afzali","year":"2025","journal-title":"United European Gastroenterol J"},{"key":"10.1053\/j.gastro.2025.09.038_bib77","article-title":"Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease","volume":"4","author":"Alayo","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"10.1053\/j.gastro.2025.09.038_bib78","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cgh.2024.05.051","article-title":"IBD matchmaking: rational combination therapy","volume":"23","author":"Battat","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib79","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cgh.2011.04.031","article-title":"Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial","volume":"9","author":"Sandborn","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib80","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.09.038_bib81","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn's disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.09.038_bib82","article-title":"Efficacy of advanced therapies in achieving remission by disease location in Crohn's disease: a systematic review and meta-analysis","author":"Lee","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"10.1053\/j.gastro.2025.09.038_bib83","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025","volume":"74","author":"Moran","year":"2025","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.09.038_bib84","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cgh.2023.12.023","article-title":"Comparative efficacy of advanced therapies for achieving endoscopic outcomes in crohn's disease: a systematic review and network meta-analysis","volume":"22","author":"Vuyyuru","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib85","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.11.267","article-title":"P082 Anti-TNF efficacy after primary vedolizumab failure in pediatric inflammatory bowel disease","volume":"158","author":"Dolinger","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib86","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1053\/j.gastro.2025.09.038_bib87","doi-asserted-by":"crossref","first-page":"468","DOI":"10.14309\/ajg.0000000000002553","article-title":"Maternal and neonatal outcomes in vedolizumab- and ustekinumab-exposed pregnancies: results from the PIANO registry","volume":"119","author":"Chugh","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.09.038_bib88","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cgh.2024.06.050","article-title":"Modern advanced therapies for inflammatory bowel diseases: practical considerations and positioning","volume":"23","author":"Fudman","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib89","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2468-1253(25)00017-2","article-title":"Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study","volume":"10","author":"Panaccione","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib90","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.cgh.2021.12.030","article-title":"Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn\u2019s disease in the CELEST extension study","volume":"20","author":"D\u2019Haens","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib91","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","volume":"186","author":"Gordon","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib92","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/ecco-jcc\/jjab093","article-title":"Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: results from the phase 2 open-label extension study","volume":"15","author":"Ferrante","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1053\/j.gastro.2025.09.038_bib93","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A controlled double blind study of azathioprine in the management of Crohn's disease","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.09.038_bib94","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0016-5085(93)90709-L","article-title":"Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease","volume":"105","author":"Ewe","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib95","first-page":"2203","article-title":"Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial","volume":"92","author":"Oren","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.09.038_bib96","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1111\/j.1572-0241.2008.02024.x","article-title":"A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease","volume":"103","author":"Reinisch","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.09.038_bib97","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn's Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib98","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/gast.2000.18144","article-title":"A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease","volume":"119","author":"Markowitz","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib99","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(78)92524-2","article-title":"Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease","volume":"2","author":"O'Donoghue","year":"1978","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.09.038_bib100","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2013.06.009","article-title":"Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease","volume":"145","author":"Panes","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib101","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.09.038_bib102","first-page":"1724","article-title":"Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Arora","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib103","first-page":"342L1627","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.09.038_bib104","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib105","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00384-006-0202-x","article-title":"Hematological malignancies in chronic inflammatory bowel diseases: report of five cases and review of the literature","volume":"22","author":"Crispino","year":"2007","journal-title":"Int J Colorectal Dis"},{"key":"10.1053\/j.gastro.2025.09.038_bib106","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.1971.03180310117023","article-title":"Pulmonary and hepatic complications of methotrexate therapy of psoriasis","volume":"216","author":"Filip","year":"1971","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2025.09.038_bib107","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib108","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ajg.2013.402","article-title":"The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis","volume":"109","author":"Chatu","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.09.038_bib109","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib110","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2023.03.224","article-title":"Comparative effectiveness of anti-TNF in combination with low-dose methotrexate vs anti-TNF monotherapy in pediatric Crohn's disease: a pragmatic randomized trial","volume":"165","author":"Kappelman","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib111","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.09.038_bib112","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib113","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","article-title":"Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: a prospective, randomized trial","volume":"10","author":"Matsumoto","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1053\/j.gastro.2025.09.038_bib114","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.gastro.2013.12.025","article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease","volume":"146","author":"Osterman","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","article-title":"Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib116","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.cgh.2015.06.034","article-title":"Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn's disease: a meta-analysis of placebo-controlled trials","volume":"13","author":"Jones","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib117","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.09.038_bib118","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cgh.2014.12.026","article-title":"Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy","volume":"13","author":"Yarur","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib119","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1016\/j.cgh.2022.10.016","article-title":"Combination therapy with immunomodulators improves the pharmacokinetics of infliximab but not vedolizumab or ustekinumab","volume":"21","author":"Yarur","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib120","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1\u221705 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib121","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1016\/j.cgh.2023.03.044","article-title":"HLA-DQA1 \u221705 genotype and immunogenicity to tumor necrosis factor-alpha antagonists: a systematic review and meta-analysis","volume":"21","author":"Solitano","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib122","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/gutjnl-2019-319758","article-title":"Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial","volume":"69","author":"Roblin","year":"2020","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.09.038_bib123","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1111\/imj.16504","article-title":"6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy","volume":"54","author":"Yu","year":"2024","journal-title":"Intern Med J"},{"key":"10.1053\/j.gastro.2025.09.038_bib124","article-title":"Effectiveness and safety of advanced combination treatment in patients with refractory inflammatory bowel disease or concomitant immune-mediated disease or extraintestinal manifestations: a multicenter Canadian study","author":"Solitano","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.09.038_bib125","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib126","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.cgh.2020.07.012","article-title":"Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab","volume":"19","author":"Hu","year":"2021","journal-title":"Clin Gastroenterolo Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib127","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.cgh.2020.06.071","article-title":"No benefit of concomitant immunomodulator therapy on efficacy of biologics that are not tumor necrosis factor antagonists in patients with inflammatory bowel diseases: a meta-analysis","volume":"19","author":"Yzet","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib128","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.3390\/jcm9103142","article-title":"Vedolizumab serum trough concentrations and response to dose escalation in inflammatory bowel disease","volume":"9","author":"Vaughn","year":"2020","journal-title":"J Clin Med"},{"key":"10.1053\/j.gastro.2025.09.038_bib129","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.cgh.2021.01.002","article-title":"Therapeutic drug monitoring of non-anti-tumor necrosis factor biologics","volume":"19","author":"Shukla","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib130","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1136\/gutjnl-2022-327002","article-title":"Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease","volume":"71","author":"Kirchgesner","year":"2022","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.09.038_bib131","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00535-019-01582-w","article-title":"Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)","volume":"54","author":"Hisamatsu","year":"2019","journal-title":"J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.09.038_bib132","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/apt.14106","article-title":"Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial","volume":"46","author":"Roblin","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.09.038_bib133","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/MPG.0000000000000684","article-title":"Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease","volume":"60","author":"Kierkus","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1053\/j.gastro.2025.09.038_bib134","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib135","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gutjnl-2024-333385","article-title":"Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU","volume":"74","author":"Gisbert","year":"2025","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.09.038_bib136","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2468-1253(22)00385-5","article-title":"Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial","volume":"8","author":"Louis","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib137","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200061","article-title":"Discontinuation of infliximab therapy in patients with Crohn's disease","volume":"1","author":"Buhl","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1053\/j.gastro.2025.09.038_bib138","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib139","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2809","article-title":"Association between tumour necrosis factor-alpha inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study","volume":"350","author":"Nyboe Andersen","year":"2015","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2025.09.038_bib140","doi-asserted-by":"crossref","first-page":"741","DOI":"10.14309\/ajg.0000000000001058","article-title":"Incidence of acute myeloid leukemia and myelodysplastic syndrome in patients with inflammatory bowel disease and the impact of thiopurines on their risk","volume":"116","author":"Khan","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.09.038_bib141","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/j.cgh.2022.01.019","article-title":"Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease","volume":"20","author":"Mahmoud","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib142","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.09.038_bib143","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.09.038_bib144","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib145","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0140-6736(17)30317-3","article-title":"Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study","volume":"389","author":"Kugathasan","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.09.038_bib146","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.7378","article-title":"Association between steroid-sparing therapy and the risk of perianal fistulizing complications among young patients with Crohn disease","volume":"3","author":"Adler","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1053\/j.gastro.2025.09.038_bib147","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/gutjnl-2024-333280","article-title":"Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study","volume":"74","author":"Adler","year":"2025","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.09.038_bib148","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-052501","article-title":"Delays related to prior authorization in inflammatory bowel disease","volume":"149","author":"Constant","year":"2022","journal-title":"Pediatrics"},{"key":"10.1053\/j.gastro.2025.09.038_bib149","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2468-1253(21)00474-X","article-title":"Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial","volume":"7","author":"Danese","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 8","key":"10.1053\/j.gastro.2025.09.038_bib150","first-page":"89","article-title":"A cluster-randomised controlled trial of an enhanced treatment algorithm for the management of Crohn\u2019s disease: REACT-2","volume":"10","author":"Jairath","year":"2022","journal-title":"United European Gastroenterol J"},{"key":"10.1053\/j.gastro.2025.09.038_bib151","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/gutjnl-2019-318256","article-title":"Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial","volume":"69","author":"Panaccione","year":"2020","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.09.038_bib152","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2018","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.09.038_bib153","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.gastro.2020.03.039","article-title":"Deep remission at 1 year prevents progression of early Crohn's disease","volume":"159","author":"Ungaro","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.09.038_bib154","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.cgh.2021.11.030","article-title":"Steroid-free deep remission at one year does not prevent Crohn's disease progression: long-term data from the TAILORIX Trial","volume":"20","author":"Laharie","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib155","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/S0140-6736(14)61908-5","article-title":"Crohn's disease management after intestinal resection: a randomised trial","volume":"385","author":"De Cruz","year":"2015","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.09.038_bib156","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.cgh.2019.11.056","article-title":"Histologic healing is more strongly associated with clinical outcomes in ileal Crohn's disease than endoscopic healing","volume":"18","author":"Christensen","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.09.038_bib157","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/apt.15190","article-title":"One-year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing","volume":"49","author":"Castiglione","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.09.038_bib158","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/MIB.0000000000001143","article-title":"Transmural healing is associated with improved long-term outcomes of patients with Crohn's disease","volume":"23","author":"Fernandes","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2025.09.038_bib159","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","article-title":"ACG Clinical Guideline: management of Crohn's disease in adults","volume":"120","author":"Lichtenstein","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.09.038_bib160","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"}],"updated-by":[{"DOI":"10.1053\/j.gastro.2025.12.013","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000}},{"DOI":"10.1053\/j.gastro.2025.12.013","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000}}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508525060913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508525060913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:16:31Z","timestamp":1776917791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508525060913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":159,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0016508525060913"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2025.09.038","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2025.09.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the AGA Institute.","name":"copyright","label":"Copyright"}]}}